fluoxetine has been researched along with Pneumonia, Viral in 3 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Pneumonia, Viral: Inflammation of the lung parenchyma that is caused by a viral infection.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fluoxetine resulted in a faster reduction of patients' inflammation without association with depression and anxiety." | 5.69 | Efficacy and safety of adding fluoxetine to the treatment regimen of hospitalized patients with non-critical COVID-19 pneumonia: A double-blind randomized, placebo-controlled clinical trial. ( Ala, S; Alizadeh Arimi, F; Elyasi, F; Ghasemian, R; Mehravaran, H; Moosazadeh, M; Sedighi, F; Zarghami, M, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sedighi, F | 1 |
| Zarghami, M | 1 |
| Alizadeh Arimi, F | 1 |
| Moosazadeh, M | 1 |
| Ala, S | 1 |
| Ghasemian, R | 1 |
| Mehravaran, H | 1 |
| Elyasi, F | 1 |
| Lim, J | 1 |
| Lee, J | 1 |
| Schloer, S | 1 |
| Brunotte, L | 1 |
| Goretzko, J | 1 |
| Mecate-Zambrano, A | 1 |
| Korthals, N | 1 |
| Gerke, V | 1 |
| Ludwig, S | 1 |
| Rescher, U | 1 |
1 trial available for fluoxetine and Pneumonia, Viral
| Article | Year |
|---|---|
Efficacy and safety of adding fluoxetine to the treatment regimen of hospitalized patients with non-critical COVID-19 pneumonia: A double-blind randomized, placebo-controlled clinical trial.
Topics: Antidepressive Agents, Second-Generation; Anxiety; C-Reactive Protein; COVID-19; Depression; Double- | 2023 |
2 other studies available for fluoxetine and Pneumonia, Viral
| Article | Year |
|---|---|
Current laboratory diagnosis of coronavirus disease 2019.
Topics: Antidepressive Agents; Betacoronavirus; China; Clinical Laboratory Techniques; Coronavirus; Coronavi | 2020 |
Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine.
Topics: Antidepressive Agents; Antiviral Agents; Betacoronavirus; Cell Line; Coronavirus Infections; COVID-1 | 2020 |